Abemaciclib for malignant pleural mesothelioma
- PMID: 35654054
- DOI: 10.1016/S1470-2045(22)00276-5
Abemaciclib for malignant pleural mesothelioma
Conflict of interest statement
We declare no competing interests.
Comment in
-
Abemaciclib for malignant pleural mesothelioma - Authors' reply.Lancet Oncol. 2022 Jun;23(6):e238. doi: 10.1016/S1470-2045(22)00285-6. Lancet Oncol. 2022. PMID: 35654055 No abstract available.
Comment on
-
Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trial.Lancet Oncol. 2022 Mar;23(3):374-381. doi: 10.1016/S1470-2045(22)00062-6. Epub 2022 Feb 11. Lancet Oncol. 2022. PMID: 35157829 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources